Hepatitis B therapies and antiviral resistance detection and management

Expert Review of Gastroenterology and Hepatology

Volumn 3, Issue 6, 2009, Pages 693-699

  Holness, Giselle ^a   Carriero, Damaris C ^a   Dieterich, Douglas T ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Biochemical breakthrough; Genotypic resistance; Hepatitis B; Virologic breakthrough

Indexed keywords

2 AMINO 9 (1 PHOSPHONOMETHOXYCYCLOPROPYLMETHYL)PURINE BIS(PIVALOYLOXYMETHYL) ESTER; ADEFOVIR; ALPHA INTERFERON; ALPHA2A INTERFERON; ANTIVIRUS AGENT; EMTRICITABINE; ENTECAVIR; LAMIVUDINE; NITAZOXANIDE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PLACEBO; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; THYMOSIN ALPHA1; VIRUS DNA;

ADD ON THERAPY; ANTIVIRAL ACTIVITY; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; BONE DENSITY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG INDICATION; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FANCONI RENOTUBULAR SYNDROME; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LONG TERM CARE; MONOTHERAPY; NONHUMAN; OSTEOMALACIA; REVIEW; SEROCONVERSION; SIDE EFFECT; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG RESISTANCE, VIRAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; TREATMENT OUTCOME;

EID: 73449106125     PISSN: 17474124     EISSN: None     Source Type: Journal    
DOI: 10.1586/egh.09.64     Document Type: Review

References (42)

1. Nguyen VT, Law MG, Dore GJ. Hepatitis B-related hepatocellular carcinoma: epidemiological characteristics and disease burden. J. Viral Hepat. 16, 453-463 (2009).
2. Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis based on the level of circulating hepatitis B viral load. Gastroenterology 130, 678-686 (2006).
3. Chen CJ, Iloeje UH, Yang HI. Long-term outcomes in hepatitis B: the REVEALHBV study. Clin. Liver Dis. 11, 797-816 (2007).
4. European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of chronic hepatitis B. J. Hepatol. 50, 227-242 (2009). •• Pivotal practice guidelines for the management of chronic hepatitis B (CHB).
5. Keeffe EB, Dieterich DT, Han S-H B et al. Special Report. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin. Gastroenterol. Hepatol. 6, 1315-1341 (2008). •• Pivotal treatment algorithm for the management of CHB.
6. Nowak MA, Bonhoeffer S, Hill AM et al. Viral Dynamics in hepatitis B virus infection. Proc. Natl Acad. Sci. USA 93(9), 4398-4402 (1996).
7. Park SG, Kim Y, Park E et al. Fidelity of hepatitis B virus polymerase. Eur. J. Biochem. 270(14), 2929-2936 (2003).
8. Zoulim F, Locarnini S. Hepatits B virus resistance to nucleos(t)ide analogues. Gastroeneterology 137(5), 1593-1608. (2009).
9. Pawlotsky JM, Dusheiko G, Hatzakis A et al. Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology 134, 405-415 (2008). • Pivotal recommendation for a standardized approach to virologic monitoring of hepatitis B.
10. Shaw T, Bartholomeusz A, Locarnini S. HBV drug resistance: mechanisms, detection and interpretation. J. Hepatol. 44, 593-606 (2006). • Pivotal recommendation for detection and interpretation of hepatitis B virus drug resistance.
11. Gish RG. Hepatitis B treatment: current best practices, avoiding resistance. Cleve. Clin. J. Med. 3, S14-S19 (2009).
12. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol. Int. 2, 263-283 (2008). •• Pivotal practice guidelines for the management of CHB.
13. Cooksley WG, Piratvisuth T, Lee SD et al. Peginterferon a-2a (40 kDa): an advance in the treatment of hepatitis B e antigenpositive chronic hepatitis B. J. Viral Hepat. 10, 298-305 (2003).
14. Lau GK, Piratvisuth T, Luo KX et al. Peginterferon a-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 352, 2682-2695 (2005).
15. Leung N. Recent data on treatment of chronic hepatitis B with nucleos(t)ide analogues. Hepatol. Int. 2(2), 163-178 (2008).
16. Chang TT, Gish RG, de Man R et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N. Engl. J. Med. 354, 1001-1010 (2006).
17. Lai CL, Shouval D, Lok AS et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 354, 1011-1020 (2006).
18. Colonno RJ, Rose R, Baldick CJ et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 44, 1656-1665 (2006).
19. Tenney DJ, Rose RE, Baldick CJ et al. Two-year assessment of entecavir resistance in Lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob. Agents Chemother. 3, 902-911 (2007).
20. Lai CL, Gane E, Liaw YF et al. Telbivudine versus lamivudine in patients with chronic hepatitis B. N. Engl. J. Med. 357, 2576-2588 (2007).
21. Liaw YF, Gane E, Leung N et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 136, 486-495 (2009).
22. Chan HL, Heathcote EJ, Marcellin P et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann. Intern. Med. 147, 745-754 (2007).
23. van Bommel F, Wunsche T, Mauss S et al. Comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus infection. Hepatology 40, 1421-1425 (2004).
24. Hann HW, Chae HB, Dunn SR. Tenofovir (TDF) has stronger antiviral effect than adefovir (ADV) against lamivudine (LAM) resistant hepatitis B virus (HBV). Hepatol. Int. 2(2), 244-249 (2008).
25. Marcellin P, Heathcote J, Buti M et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N. Engl. J. Med. 23, 2442-2455 (2008).
26. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 50, 661-662 (2009). •• Pivotal practice guidelines for the management of CHB.
27. Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 32, 866-867 (2000).
28. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 131, 1743-1751 (2006).
29. Tenney DJ, Pokorowski KA, Rose RE et al. Entecavir maintains a high genetic barrier to HBV resistance through 6 years in naive patients. Prsented at: EASL 44th Annual Meeting. Copenhagen, Denmark, 22-26 April 2009.
30. Lok AS, Zoulim F, Locarnini S et al. Antiviral drug-resistant HBV: standardization of nomenclature and assays and recommendations for management. Hepatology 46, 254-265 (2007). •• Pivotal practice guidelines for the management of CHB.
31. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant in HBeAg-negative chronic hepatitis B. Hepatology 45, 307-313 (2007).
32. Chevaliez S, Pawlotsky JM. Virological techniques for the diagnosis and monitoring of hepatitis B and C. Ann. Hepatol. 8, 7-12 (2009).
33. Lampertico P, Vigano M, Manenti E, Iavarone M, Sablon E, Colombo M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 133, 1445-1451 (2007).
34. Pollicino T, Isgro G, Di Stefano R et al. Variability of reverse transcriptase and overlapping S gene in hepatitis B virus isolates from untreated and lamivudineresistant chronic hepatitis B patients. Antivir. Ther. 14(5), 649-654 (2009).
35. Keeffe EB, Zeuzem S, Koff, RS et al. Report of an international workshop: Roadmap for management of patients receiving oral therapy for chronic hepatitis B. Clin. Gastroenterol. Hepatol. 5, 890-897 (2007).
36. Yuen MF, Fung J, Wong DK, Lai CL. Prevention and management of drug resistance for antihepatitis B treatment. Lancet Infect. Dis. 9, 256-264 (2009).
37. Seok Jl, Lee DK, Lee CH et al. Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA. J. Hepatol. 49(6), 2080-2086 (2009).
38. Lim SG, Ng TM, Kung N et al. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B. Arch. Intern. Med. 166(1), 49-56 (2006).
39. Keeffe EB, Rossignol JF. Treatment of chronic viral hepatitis with nitazoxanide and second generation thiazolides. World J. Gastroenterol. 15, 1808-1808 (2009).
40. Chan HL, Tang JL, Tam W, Sung JJ. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment. Pharmacol. Ther. 15, 1899-1905 (2001).
41. Terrault N. Benefits and risks of combination therapy for hepatitis B. Hepatology 49(5 Suppl.), S122-S128 (2009).
42. Seetharam A, Lisker-melman M. Treatment of chronic hepatitis B: are we ready for combination therapy? Liver 11, 22-27 (2009).